RedHill Biopharma (RDHL) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. MRNA
9. LVS
10. MRK

Go back to RedHill Biopharma (RDHL) Tops Q2 EPS by 3c

RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights

August 13, 2020 7:00 AM EDT

Q2/2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively

-- Completed acquisition of Movantik® from AstraZeneca and secured exclusive control over U.S. commercialization through new royalty-bearing agreement with Daiichi Sankyo -- Talicia® added as an unrestricted branded agent to three major national formularies, providing a strong platform for continued prescription growth -- Entered into binding term sheet with Cosmo Pharmaceuticals for exclusive licensing and manufacturing agreement for multiple products, under which RedHill is... More